The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Open accessPreprint — published as 10.1038/s41586-020-2639-4 · Paper page
Abstract
In March 2020, the WHO declared a pandemic of coronavirus disease 2019 (COVID-19), due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 With >8.8 million cases and >450,000 deaths reported globally, a vaccine is urgently needed. We report the available safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among healthy adults, 18-55 years of age, randomized to receive 2 doses, separated by 21 days, of 10 μg, 30 μg, or 100 μg of BNT162b1, a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers in sera increased with dose level and after a second dose. Geometric mean neutralizing titers reached 1.8-to 2.8-fold that of a panel of COVID-19 convalescent human sera. These results support further evaluation of this mRNA vaccine candidate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The incidence of grade 3 fever of BNT162b1 varied significantly in the same 30 μg group in adults aged 18–55 years, with none (0%) of 12 in the USA,17 one (8%) of 12 in Germany,18 and four (17%) of 24 in China,16 suggesting varying tolerability in different populations.”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Together with recent reports of the preserved neutralization of SARS-CoV-2 with key S mutations found in the B.1.1.7 and the B.1.351lineage 39,40 , and neutralization of pseudovirus bearing the full set of mutations of B.1.1.7 S 41 , our data indicate broad BNT162b2-elicited immune recognition 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To enable the comparison of vaccine-induced S1-and RBD-binding IgG responses to previously reported data on the BioNTech-Pfizer RNA vaccines for COVID-19, sera were analysed as previously described 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GMTs in subgroups of the donors were as follows: symptomatic infections, 90 (n = 35); asymptomatic infections, 156 (n = 3); hospitalized, 618 (n = 1).”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meanwhile, several studies17, 18, 19 have reported more frequent and severe solicited systemic adverse events following the second vaccination than we found.”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies17, 18, 19 showed that solicited systemic adverse events were more frequent and more severe at higher doses”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This contrasts with recent reports of mRNA-LNP vaccines against the SARS-CoV-2 virus responsible for the COVID-19 pandemic which had similar rates of reactogenicity and in which reactogenicity noticeably increased after a second dose [17], [18].”
From Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The S glycoprotein mediates host cell attachment and is required for viral entry3; it is the primary vaccine target for many candidate SARS-CoV-2 vaccines.4-7”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those studies showed that solicited systemic adverse events tended to be more frequent and more severe with higher doses and after the second vaccination.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To enable the comparison of vaccine-induced serum neutralizing titres to those previously reported for BioNTech-Pfizer RNA vaccines for COVID-19, sera were analysed as previously described 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“This descriptive safety profile is similar to that described in a report of two trials of avian influenza mRNA vaccines (influenza A/H10N8 and influenza A/H7N9) that were manufactured by Moderna with the use of an earlier lipid nanoparticle capsule formulation11 and is consistent with an interim report of a phase 1–2 evaluation of a Covid-19 mRNA vaccine encoding the S receptor-binding domain.6”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the use of high doses of mRNA formulated with lipid nanoparticles (LNPs) resulted in some side effects in the candidates mRNA-1273 and BNT162b1.3,4”
From Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA (2021) · cites this paper as [4]
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [152]
In the citing paper
“an mRNA-based vaccine that encodes the full-length SARS-CoV-2 spike (S) gene1”
From SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses (2021) · cites this paper as [1]
In the citing paper
“However, the vaccine developers eventually decide to proceed with BNT162b2 to phase II/III international clinical trials in view of its milder reactogenicity.277,278,378”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [378]
In the citing paper
“BioNTech and Pfizer collaborated to develop five COVID-19 mRNA vaccine candidates at the beginning of the pandemic, which were based on nucleoside-modified mRNA (BNT162b2, BNT162b1, BNT162b3), non-modified mRNA (BNT162a1) and self-amplifying mRNA (BNT162c2).”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [376]
In the citing paper
“Clinical trial data indicated that both mRNA vaccine candidates induced neutralizing antibodies at a comparable level.”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [378]
In the citing paper
“Till now, all of these candidates have entered clinical trials (Table 5).130,376,377”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [376]
In the citing paper
“8–50-fold higher anti-RBD IgG”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“1.9–4.6-fold higher neutralization titres than convalescent serum27,123”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“In phase I trials of the two candidates, two 30 μg doses delivered 21 days apart induced high antibody and neutralizing titres and a robust CD4+ and CD8+ response with mild to moderate adverse events27,28,123,124.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“with up to 75% showing moderate fever after a 30 μg boost vaccine [82].”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Both local and systemic AE occurred dose-dependently, were mostly mild to moderate and more common after boost vaccination.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“events also peaked at day 2 after dosing and were resolved by day 7.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“despite the lower mRNA-doses used, AEs were reported more frequently with BNT162b1 as compared to mRNA-1273”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Based on the reactogenicity to the 100 μg dose, no boost vaccination was performed at this dosage.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“fever was already reported after the first vaccination for all dose groups (8% for the 10 and 30 μg doses, 50% for the 100 μg dose)”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Results of a phase 1/2 dose-escalation study (mRNA doses of 10–30-100 μg) revealed similar tolerability and safety.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationPersonalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Self-citationCOVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationCoronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020.
Stokes, E. K., Zambrano, L. D., Anderson, K. N., Marder, E. P., Raz, K. M., El Burai Felix, S., Tie, Y., & Fullerton, K. E. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6924e2 · Cited by 1,538
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
An Infectious cDNA Clone of SARS-CoV-2
Xie, X., Muruato, A., Lokugamage, K. G., Narayanan, K., Zhang, X., Zou, J., Liu, J., Schindewolf, C., Bopp, N. E., Aguilar, P. V., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.004 · Cited by 647
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,004
The role of micronutrient and immunomodulation effect in the vaccine era of COVID-19
Lai, Y.-J., Chang, H.-S., Yang, Y., Lin, T.-W., Lai, W.-Y., Lin, Y., & Chang, C. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000587 · Cited by 34
Immunity after COVID-19 Recovery and Vaccination: Similarities and Differences
Kamińska, D., Dęborska−Materkowska, D., Kościelska−Kasprzak, K., Mazanowska, O., Remiorz, A., Poznański, P., Durlik, M., & Krajewska, M. (2022) · Vaccines · doi:10.3390/vaccines10071068 · Cited by 33
Effectiveness of COVID‑19 vaccines and their challenges (Review)
Marfè, G., Perna, S., & Shukla, A. K. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10843 · Cited by 32
Warmiński, M., Kowalska, J., Nowak, E., Kubacka, D., Tibble, R. W., Kasprzyk, R., Sikorski, P. J., Gross, J. D., Nowotny, M., & Jemielity, J. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.0c00864 · Cited by 31
mRNA-Based Vaccines and Mode of Action
Gergen, J., & Petsch, B. (2020) · Current topics in microbiology and immunology · doi:10.1007/82_2020_230 · Cited by 36
Rahman, M. M., Zhou, N., & Huang, J. (2021) · Vaccines · doi:10.3390/vaccines9030244 · Cited by 32
Magadum, A., Singh, N., Kurian, A. A., Sharkar, M. T. K., Sultana, N., Chepurko, E., Kaur, K., Żak, M. M., Hadas, Y., Lebeche, D., et al. (2021) · Advanced Science · doi:10.1002/advs.202004661 · Cited by 30
Noble Metal Organometallic Complexes Display Antiviral Activity against SARS-CoV-2
Chuong, C., DuChane, C. M., Webb, E. M., Rai, P., Marano, J. M., Bernier, C. M., Merola, J. S., & Weger‐Lucarelli, J. (2021) · Viruses · doi:10.3390/v13060980 · Cited by 31
Abu‐Halaweh, S. A., Alqassieh, R., Suleiman, A., Al-Sabbagh, M. Q., Abu-Halaweh, M., Alkhader, D., Abu-Nejem, R., Nabulsi, R., Al‐Tamimi, M., Alwreikat, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9090950 · Cited by 33
Mitsunaga, T., Ohtaki, Y., Seki, Y., Yoshioka, M., Mori, H., Suzuka, M., Mashiko, S., Takeda, S., & Mashiko, K. (2021) · PeerJ · doi:10.7717/peerj.12316 · Cited by 32
Barghash, R. F., Fawzy, I. M., Chandrasekar, V., Singh, A. V., Katha, U., & Mandour, A. A. (2021) · Coatings · doi:10.3390/coatings11111273 · Cited by 31
Hashemi, B., Firouzi‐Amandi, A., Amirazad, H., Dadashpour, M., Sheervalilou, M., Nasrabadi, D., Ahmadi, M., Sheervalilou, R., Reza, M. A. S., Ghazi, F., et al. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102967 · Cited by 31
Valentin, A., Bergamaschi, C., Rosati, M., Angel, M., Burns, R., Agarwal, M., Gergen, J., Petsch, B., Oostvogels, L., Loeliger, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945706 · Cited by 32
Lindelöf, G., Aledavood, T., & Keller, B. (2023) · Journal of Medical Internet Research · doi:10.2196/41319 · Cited by 36
Effective gene therapy of Stargardt disease with PEG-ECO/pGRK1-ABCA4-S/MAR nanoparticles
Sun, D., Sun, W., Gao, S., Lehrer, J., Naderi, A., Wei, C., Lee, S.-J., Schilb, A. L., Scheidt, J. H., Hall, R. C. W., et al. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.08.026 · Cited by 31
Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications
Prabhakar, P. K., Khurana, N., Vyas, M., Sharma, V., Batiha, G. E., Kaur, H., Singh, J., Kumar, D., Sharma, N., Kaushik, A. K., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020451 · Cited by 32
Doherty, J., Fennessy, S., Stack, R., Morain, N. O., Cullen, G. J., Ryan, E. J., Gascun, C. F. D., & Doherty, G. A. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16590 · Cited by 29
Ferrari, D., Clementi, N., Criscuolo, E., Ambrosi, A., Corea, F., Resta, C. D., Tomaiuolo, R., Mancini, N., Locatelli, M., Plebani, M., et al. (2021) · Vaccines · doi:10.3390/vaccines9111357 · Cited by 31
Ghani, M. W., Iqbal, A., Ghani, H., Bibi, S., Wang, Z., & Pei, R. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02610d · Cited by 32
Vaccination is the most effective and best way to avoid the disease of COVID‐19
Lotfi, H., Mazar, M. G., Ei, N. M. H., Fahim, M., & Yazdi, N. S. (2023) · Immunity Inflammation and Disease · doi:10.1002/iid3.946 · Cited by 33
Current progress and challenges in the design and development of a successful COVID-19 vaccine
Li, T., Zhang, T., Gu, Y., Li, S., & Xia, N. (2021) · Fundamental Research · doi:10.1016/j.fmre.2021.01.011 · Cited by 30
mRNA-Enhanced Cell Therapy and Cardiovascular Regeneration
Chanda, P. K., Sukhovershin, R. A., & Cooke, J. P. (2021) · Cells · doi:10.3390/cells10010187 · Cited by 30
Zoratto, N., Montanari, E., Viola, M., Wang, J., Coviello, T., Meo, C. D., & Matricardi, P. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118119 · Cited by 32
El-Menyar, A. A., Mekkodathil, A. A., Asim, M., Consunji, R. J., Rizoli, S. B., Bahey, A. A., & Al-Thani, H. A. S. (2021) · Science Progress · doi:10.1177/00368504211016936 · Cited by 33
Li, J., Men, K., Gao, Y., Wu, J., Lei, S., Yang, Y., & Pan, H. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00461 · Cited by 30
Bewley, K. R., Gooch, K. E., Thomas, K. M., Longet, S., Wiblin, N. R., Hunter, L. E., Chan, K., Brown, P. J., Russell, R. A., Ho, C. M. K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg7996 · Cited by 27
Tuan, J., Zapata, H. J., Critch‐Gilfillan, T., Ryall, L., Turcotte, B., Mutic, S., Andrews, L., Roh, M. E., Friedland, G. H., Barakat, L., et al. (2021) · HIV Medicine · doi:10.1111/hiv.13188 · Cited by 30
Kleen, T. O., Galdon, A. A., MacDonald, A. S., & Dalgleish, A. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02059 · Cited by 29
McGill, A. R., Khalil, R., Dutta, R., Green, R. J., Howell, M., Mohapatra, S., & Mohapatra, S. S. (2021) · Infectious Disease Reports · doi:10.3390/idr13010013 · Cited by 30
Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19
Ni, Y., Alu, A., Hong, L., Wang, Y., Wu, M., & Wei, X. (2021) · Molecular Biomedicine · doi:10.1186/s43556-020-00015-y · Cited by 32
Combating Human Viral Diseases: Will Plant-Based Vaccines Be the Answer?
Venkataraman, S., Hefferon, K. L., Makhzoum, A. B., & Haidar, M. A. (2021) · Vaccines · doi:10.3390/vaccines9070761 · Cited by 33
Secret messengers: Extracellular RNA communication in the immune system
Nation, G. K., Saffold, C. E., & Pua, H. H. (2021) · Immunological Reviews · doi:10.1111/imr.13027 · Cited by 28
Haranaka, M., Baber, J., Ogama, Y., Yamaji, M., Aizawa, M., Kogawara, O., Scully, I. L., Lagkadinou, E., Türeci, Ö., Şahin, U., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27316-2 · Cited by 28
Self-citationUrakawa, R., Isomura, E. T., Matsunaga, K., Kubota, K., & Ike, M. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07175-y · Cited by 29
Fujigaki, H., Yamamoto, Y., Koseki, T., Banno, S., Ando, T., Ito, H., Fujita, T., Naruse, H., Hata, T., Moriyama, S., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01181-21 · Cited by 30
Chemo-Enzymatic Modification of the 5′ Cap To Study mRNAs
Bollu, A., Peters, A., & Rentmeister, A. (2022) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00059 · Cited by 30
Toledo-Romaní, M. E., Carmenate, M. G., Verdecia-Sánchez, L., Pérez-Rodríguez, S., Rodriguez-González, M., Valenzuela‐Silva, C., Paredes-Moreno, B., Sánchez-Ramírez, B., González-Mugica, R., Hernández-García, T., et al. (2022) · Med · doi:10.1016/j.medj.2022.08.001 · Cited by 30
mRNA vaccines: A novel weapon to control infectious diseases
Tian, Y., Deng, Z., & Yang, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1008684 · Cited by 29
Ohno, H., Akamine, S., Mochizuki, M., Hayashi, K., Akichika, S., Suzuki, T., & Saito, H. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad019 · Cited by 31
Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
Robertson, J. F. R., Sewell, H. F., & Stewart, M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00455-4 · Cited by 26
Pottoo, F. H., Abu‐Izneid, T., Ibrahim, A. M., Javed, M. N., Alhajri, N., & Hamrouni, A. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.12.018 · Cited by 30
The role and uses of antibodies in COVID-19 infections: a living review
Scourfield, D. O., Reed, S. G., Quastel, M. N., Alderson, J., Bart, V. M. T., Crespo, A. T., Jones, R. E., Pring, E., Richter, F. C., Ahern, D., et al. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab003 · Cited by 30
Al-Hatamleh, M. A. I., Hatmal, M. M., Alshaer, W., Rahman, E. N. S. E. A., Mohd-Zahid, M. H., Alhaj-Qasem, D. M., Yean, C. Y., Alias, I. Z., Jaafar, J., Ferji, K., et al. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173930 · Cited by 28
A Biochemical Perspective of the Nonstructural Proteins (NSPs) and the Spike Protein of SARS CoV-2
Yoshimoto, F. K. (2021) · The Protein Journal · doi:10.1007/s10930-021-09967-8 · Cited by 28
Clinical Management of COVID-19: A Review of Pharmacological Treatment Options
Heustess, A., Allard, M., Thompson, D. K., & Fasinu, P. S. (2021) · Pharmaceuticals · doi:10.3390/ph14060520 · Cited by 28
Caliskan, I., Buluş, E., Afşar, N., & Altıntaş, A. (2022) · The Neurologist · doi:10.1097/nrl.0000000000000420 · Cited by 28
Hemophagocytic lymphohistiocytosis after SARS-CoV-2 vaccination
Hieber, M.-L., Sprute, R., Eichenauer, D. A., Hallek, M. J., & Jachimowicz, R. D. (2022) · Infection · doi:10.1007/s15010-022-01786-y · Cited by 28
Tang, K., Hsu, B., & Chen, D. (2022) · Biomedicines · doi:10.3390/biomedicines10040834 · Cited by 27
Sandoval, C., Guerrero, D., Muñoz, J., Godoy, K., Souza‐Mello, V., & Farías, J. G. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2156861 · Cited by 30
SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions
Timmers, L. F. S. M., Peixoto, J. V., Ducati, R. G., Bachega, J. F. R., Pereira, L. D. M., Caceres, R. A., Majolo, F., da Silva, G. L., Anton, D. B., Dellagostin, O. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91585-6 · Cited by 30
Declercq, J., Gerlo, S., Nevel, S. V., Ruyck, N. D., Holtappels, G., Delesie, L. M., Tobback, E., Lammens, I., Gerebtsov, N., Sedeyn, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn2364 · Cited by 28
Eberhardt, K. A., Dewald, F., Heger, E., Gieselmann, L., Vanshylla, K., Wirtz, M., Kleipass, F., Johannis, W., Schommers, P., Gruell, H., et al. (2021) · Microorganisms · doi:10.3390/microorganisms9040733 · Cited by 26
Biomineralization: Biomimetic Synthesis of Materials and Biomimetic Regulation of Organisms
Ma, Z., Li, B., & Tang, R. (2021) · Chinese Journal of Chemistry · doi:10.1002/cjoc.202100119 · Cited by 28
Zheng, W., Wu, H. M., Wang, T., Zhan, S., & Liu, X. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab199 · Cited by 28
Lessons Learned from Post–COVID-19 Vaccination PET/CT Studies
Orevi, M., Chicheportiche, A., & Ben‐Haim, S. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262348 · Cited by 27
Pommerenke, C., Rand, U., Uphoff, C. C., Nagel, S., Zaborski, M., Hauer, V., Kaufmann, M., Meyer, C., Denkmann, S. A., Riese, P., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255622 · Cited by 26
Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination
Yamada, S., & Asakura, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063338 · Cited by 33
Li, P., Guan, Y., Zhou, S., Wang, E., Sun, P., Fei, G., Zeng, D., & Wang, R. (2022) · Science Progress · doi:10.1177/00368504221110858 · Cited by 27
Self-citationDNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice
Szurgot, I., Hanke, L., Sheward, D. J., Vidakovics, L. P., Murrell, B., McInerney, G. M., & Liljeström, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-82498-5 · Cited by 26
SARS-CoV-2 serology testing: Progress and challenges
Shi, A. C., & Ren, P. (2021) · Journal of Immunological Methods · doi:10.1016/j.jim.2021.113060 · Cited by 28
Pawlowski, C., Lenehan, P. J., Puranik, A., Agarwal, V., Venkatakrishnan, A., Niesen, M. J. M., O’Horo, J. C., Badley, A. D., Halamka, J. D., & Soundararajan, V. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/y6pdw · Cited by 27
Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines
Abdel-Moneim, A. S., Abdelwhab, E. M., & Memish, Z. A. (2021) · Virology · doi:10.1016/j.virol.2021.02.007 · Cited by 27
Vickers, M. A., Sariol, A., Leon, J., Ehlers, A., Locher, A. V., Dubay, K. A., Collins, L. J., Voss, D. R., Odle, A. E., Holida, M. D., et al. (2021) · Transfusion · doi:10.1111/trf.16401 · Cited by 23
Comparative Analysis of Antigen-Specific Anti–SARS-CoV-2 Antibody Isotypes in COVID-19 Patients
Fujigaki, H., Inaba, M., Osawa, M., Moriyama, S., Takahashi, Y., Suzuki, T., Yamase, K., Yoshida, Y., Yagura, Y., Oyamada, T., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001369 · Cited by 27
Specific Treatment Exists for SARS-CoV-2 ARDS
Kanwar, B. A., Khattak, A., Lee, J., Balentine, J., Kast, R. E., Oh, S.-S., Sergi, C., & Lee, J. (2021) · Vaccines · doi:10.3390/vaccines9060635 · Cited by 28
Ferrari, D., Resta, C. D., Tomaiuolo, R., Sabetta, E., Pontillo, M., Motta, A., & Locatelli, M. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.06.020 · Cited by 26
Shalash, A. O., Hussein, W. M., Skwarczyński, M., & Tóth, I. (2021) · Advanced Science · doi:10.1002/advs.202100985 · Cited by 25
Nitahara, Y., Nakagama, Y., Kaku, N., Candray, K., Michimuko, Y., Tshibangu-Kabamba, E., Kaneko, A., Yamamoto, H., Mizobata, Y., Kakeya, H., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00965-21 · Cited by 25
Tharmaraj, D., Dendle, C., Polkinghorne, K. R., & Mulley, W. R. (2021) · Transplant Infectious Disease · doi:10.1111/tid.13749 · Cited by 26
Jamshidi, E., Asgary, A., Shafiekhani, P., Khajeamiri, Y., Mohamed, K., Esmaily, H., Rahi, S. J., & Mansouri, N. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2037384 · Cited by 25
Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants
Liu, C., Rcheulishvili, N., Shen, Z., Papukashvili, D., Xie, F., Wang, Z., Wang, X., He, Y., & Wang, P. G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051101 · Cited by 27
Navalón-López, M., Dols-Pérez, A., Grijalvo, S., Fornaguera, C., & Borrós, S. (2023) · Nanoscale Advances · doi:10.1039/d2na00800a · Cited by 27
SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
Sunagar, R., Singh, A., & Kumar, S. (2023) · Vaccines · doi:10.3390/vaccines11040849 · Cited by 31
Rong, Z., Mai, H., Kapoor, S., Puelles, V. G., Czogalla, J., Schädler, J., Vering, J., Delbridge, C., Steinke, H., Frenzel, H., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.04.535604 · Cited by 26
mRNA-delivery of IDO1 suppresses T cell-mediated autoimmunity
Kenney, L. L., Chiu, R. S.-Y., Dutra, M. N., Wactor, A., Honan, C., Shelerud, L. M., Corrigan, J. J., Yu, K. J., Ferrari, J. D., Jeffrey, K. L., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101717 · Cited by 28
Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic
Chakraborty, C., Sharma, A. R., Bhattacharya, M., Sharma, G., Saha, R. P., & Lee, S. (2021) · Immune Network · doi:10.4110/in.2021.21.e5 · Cited by 26
Development of COVID-19 vaccines utilizing gene therapy technology
Nakagami, H. (2021) · International Immunology · doi:10.1093/intimm/dxab013 · Cited by 25
Strategies for Immunomonitoring after Vaccination and during Infection
Adam, L., Rosenbaum, P., Bonduelle, O., & Combadière, B. (2021) · Vaccines · doi:10.3390/vaccines9040365 · Cited by 25
Luo, S., Zhang, P., Liu, B., Yang, C., Liang, C., Wang, Q. M., Zhang, L., Tang, X., Li, J., Hou, S., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1931466 · Cited by 24
Yim, J., Lim, H. H., & Kwon, Y. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01331-9 · Cited by 26
Xu, K., An, Y., Li, Q., Huang, W., Han, Y., Zheng, T., Fang, F., Liu, H., Liu, C., Gao, P., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1959270 · Cited by 25
Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges
Kandimalla, R. J. L., Chakraborty, P., Vallamkondu, J., Chaudhary, A., Samanta, S., Reddy, P. H., Feo, V. D., & Dewanjee, S. (2021) · Biomedicines · doi:10.3390/biomedicines9111740 · Cited by 25
Bonhomme, M., Bonhomme, C. J., Strelow, L. I., Chaudhari, A. A., Howlett, A., Breidenbach, C., Hester, J., Hammond, C., Fuzy, M., Harvey, L., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262922 · Cited by 21
Various vaccine platforms in the field of COVID-19
Savina, K. F., Sreekumar, R., Soonu, V. K., & Variyar, E. J. (2022) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-022-00215-1 · Cited by 26
Antibody-mediated immunity to SARS-CoV-2 spike
Errico, J. M., Adams, L. J., & Fremont, D. H. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.07.001 · Cited by 22
Silica Nanoparticles with Virus-Mimetic Spikes Enable Efficient siRNA Delivery In Vitro and In Vivo
Fu, J., Han, W., Zhang, X., Sun, Y., Bhadane, R. N., Wei, B., Li, L., Yu, L., Yang, J. B., Rosenholm, J. M., et al. (2022) · Research · doi:10.34133/research.0014 · Cited by 25
Mallah, S. I., AlAwadhi, A. I., Jawad, J. S., Wasif, P., Alsaffar, B., Alalawi, E., Mohamed, A., Butler, A. E., Alalawi, B., Qayed, D., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.032 · Cited by 27
Lu, Y., Qian, C., Huang, Y., Ren, T., Xie, W., Xia, N., & Li, S. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145501 · Cited by 28
Mining the CD4 antigen repertoire for next-generation tuberculosis vaccines
Vidal, S. J., Lasrado, N., Tostanoski, L. H., Chaudhari, J., Mbiwan, E. R., Neka, G. D., Strutton, E. A., Perez, A. A. E., Sellers, D., Barrett, J., et al. (2025) · Cell · doi:10.1016/j.cell.2025.08.027 · Cited by 26
Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2
Furuse, Y., & Oshitani, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.583252 · Cited by 24
Racing to immunity: Journey to a COVID‐19 vaccine and lessons for the future
Fernández, E. C., & Zhu, L. Y. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14686 · Cited by 24
Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges
Anthony, D. P. S., Sivakumar, K., Venugopal, P., Sriram, D. K., & George, M. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01022-9 · Cited by 23
Sathian, B., Asim, M., Banerjee, I., Roy, B., Pizarro, A. B., Mancha, M. A., van Teijlingen, E., Kord‐Varkaneh, H., Mekkodathil, A. A., Subramanya, S. H., et al. (2021) · Nepal Journal of Epidemiology · doi:10.3126/nje.v11i1.36163 · Cited by 23
Interaction of serum proteins with SARS-CoV-2 RBD
Yin, Y., Sheng, Y.-J., Wang, M., Ma, Y., & Ding, H. (2021) · Nanoscale · doi:10.1039/d1nr02687a · Cited by 22
COVID-19 Vaccines: Current Conditions and Future Prospects
Zieneldien, T., Kim, J., Cao, J. A., & Cao, C. (2021) · Biology · doi:10.3390/biology10100960 · Cited by 24
Sheng‐Kai, K., Lee, C., Liu, K., Wei, J. C., Lee, Y., & Wang, L. (2021) · Pathogens · doi:10.3390/pathogens10121537 · Cited by 24
Ahmed, S., Khan, M. S. A. A., Gayathri, S., Singh, R., Kumar, S., Patel, U. R., Malladi, S. K., Rajmani, R. S., van Vuren, P. J., Riddell, S., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765211 · Cited by 25
Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients
Guarino, M., Esposito, I., Portella, G., Cossiga, V., Loperto, I., Tortora, R., Cennamo, M., Capasso, M., Terracciano, D., Lanza, A. G., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.01.012 · Cited by 24
Dellino, M., Cascardi, E., Vinciguerra, M., Lamanna, B., Malvası, A., Scacco, S., Acquaviva, S., Pinto, V., Vagno, G. D., Cormio, G., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169136 · Cited by 25
Innate immune responses to three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine
Saresella, M., Piancone, F., Marventano, I., Hernis, A., Trabattoni, D., Invernizzi, M., Rosa, F. L., & Clerici, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.947320 · Cited by 24
Metadata
- Authors
- Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P.-Y., Türeci, Ӧ., Tompkins, K. R., Walsh, E. E., Frenck, R., Falsey, A. R., Dormitzer, P. R., Gruber, W. C., Şahin, U., & Jansen, K. U.
- Affiliations
- NYU Langone Health (US)
- University of Maryland, Baltimore (US)
- Pfizer (United Kingdom) (GB)
- Pfizer (United States) (US)
- The University of Texas Medical Branch at Galveston (US)
- Rochester General Hospital (US)
- Cincinnati Children's Hospital Medical Center (US)
- BioNTech (Germany) (DE)
- Corresponding author
- Absalon, Judith
- ORCID
- Mulligan, Mark J.
- Lyke, Kirsten E.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Neuzil, Kathleen
- Raabe, Vanessa
- Swanson, Kena A.
- Li, Ping
- Cooper, David
- Fontes-Garfias, Camila
- Shi, Pei-Yong
- Tompkins, Kristin R.
- Walsh, Edward E.
- Frenck, Robert
- Falsey, Ann R.
- Dormitzer, Philip R.
- Gruber, William C.
- Şahin, Uğur
- Jansen, Kathrin U.
- Venue
- Nature
- Publisher
- openRxiv
- Published
- 2020-07-01
- Volume
- 586
- Issue
- 7830
- Pages
- 589-593
- ISSN
- 0028-0836 (ISSN-L)
- OpenAlex
- W3048620154
- Cited by
- 1,569
- References
- 24
- Citations by year
- 2026: 47 · 2025: 92 · 2024: 111 · 2023: 183 · 2022: 355 · 2021: 623 · 2020: 152
- FWCI
- 43.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Pfizer
- Cincinnati Children's Hospital Medical Center
- University of Rochester
- Georgia Clinical and Translational Science Alliance
- National Institutes of Health (UL1TR001445)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, dose escalation, vaccine safety, vaccine immunogenicity, neutralizing antibodies, reactogenicity, healthy adults
- MeSH terms
- COVID-19, COVID-19 Vaccines, COVID-19 Serotherapy, Adult, Antibodies, Viral, Female, Humans, Immunoglobulin G, Immunization, Passive, Male, Middle Aged, Pneumonia, Viral, Time Factors, Viral Vaccines, Coronavirus Infections, Young Adult, Antibodies, Neutralizing, Pandemics, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
